Business
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":" BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET.\n\n\nThe presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.\n\n\nAbout Edgewise Therapeutics\n\n\nEdgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250304316655/en/\n\nEdgewise Contacts\nInvestors:\nMichael Carruthers, Chief Financial Officer\[email protected]\n\n\nMedia:\nMaureen Franco, VP Corporate Communications\[email protected]\n\n\nSource: Edgewise Therapeutics","length":4455,"tagName":"div"}]